Advertisement

High-dose chemotherapy in non-Hodgkin’s lymphoma

  • Jean-Yves Blay
  • Thierry O. Philip
Part of the Cancer Treatment and Research book series (CTAR, volume 85)

Abstract

The first reports of high-dose chemotherapy (HDC) and bone marrow transplantation (BMT) in non-Hodgkin’s lymphoma (NHL) were published 15 years ago, but the indications of HDC in the treatment of NHL still remains controversial [1,2]. The Consensus Conference on the Indications of HDC, which was held in Lyon in 1993, has concluded that there was no clinical situation in which HDC could be considered as a standard treatment in NHL [1,2].

Keywords

Clin Oncol Follicular Lymphoma Peripheral Blood Stem Cell Bone Marrow Involvement Autologous Bone Marrow Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Coiffier B, Philip T, Burnett AK, Symann M (1994). Consensus conference on Intensive Chemotherapy plus Hematopoietic Stem Cell Transplantation in Malignancies, June 4-6, 1994. Lyon, France. J Clin Oncol 12:226–231.PubMedGoogle Scholar
  2. 2.
    Coiffier B, Philip T, Burnett AK, Symann M (1994). Consensus conference on Intensive Chemotherapy plus Hematopoietic Stem Cell Transplantation in Malignancies, June 4-6, 1994. Lyon, France. Ann Oncol 5:19–23.PubMedGoogle Scholar
  3. 3.
    Weisenburger DD (1994). Epidemiology of non Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 5(Suppl 1):S19–S24.Google Scholar
  4. 4.
    Fisher RL, Gaynor ER, Dahlberg S, et al. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin’s lymphoma. N Engl J Med 328:1002–1006.PubMedCrossRefGoogle Scholar
  5. 5.
    Horning SJ (1993). Low-grade lymphoma 1993: state of the art. Ann Oncol (Suppl 2):S23–S27.Google Scholar
  6. 6.
    Coltman CA, Dahlberg S, Jones SE, et al. (1987). CHOP is curative in thirty percent of patients with large cell lymphomas: a twelve-year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 5:197 (abstract).Google Scholar
  7. 7.
    Klimo P, Connors JM (1985). MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102:596–602.PubMedGoogle Scholar
  8. 8.
    Skarin AT, Canellos GP, Rosenthal DS, et al. (1983). Improved prognosis of diffuse histiocytic and undifferenciated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1:91–96.PubMedGoogle Scholar
  9. 9.
    Coiffier B, Tilly H, Bosly A, Sebban C, Herbrecht R, Gisselbrecht (1993). Long term follow-up of the 737 aggressive lymphoma patients treated with the LNH84 protocol: very few relapses after 5 years. Blood 82:444a (abstract).Google Scholar
  10. 10.
    Appelbaum FR, Herzig GP, Ziegler JL, et al. (1978). Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52:85–95.PubMedGoogle Scholar
  11. 11.
    Appelbaum FR, Thomas ED (1983). Review of the use of marrow transplantation in the treatment of non Hodgkin’s lymphoma. J Clin Oncol 1:440–447.PubMedGoogle Scholar
  12. 12.
    Gulati SC, Shank B, Black L, et al. (1988). Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 6:1303–1313.PubMedGoogle Scholar
  13. 13.
    Gianni AM, Bregni M, Siena S, et al. (1991). Prospective randomized comparison of MACOP-B vs rGM-CSF supported high dose sequential myeloablative chemotherapy in diffuse large cell lymphoma. Proc Am Soc Clin Oncol 10:274 (abstract).Google Scholar
  14. 14.
    Haioun C, Lepage E, Gisselbrecht C, et al. (1993). Comparison of autologous bone marrow transplantation with sequential chemotherapy for aggressive non Hodgkin’s lymphoma (NHL) in first complete remission: a study on 464 patients (LNH87 protocol). Blood 82:87a (abstract).Google Scholar
  15. 15.
    Tura S, Zinzani PL, Mazza P, et al. (1992). ABMT vs DHAP in residual disease following third generation regimens for agressive non Hodgkin’s lymphoma. Blood 80(Suppl 1):157 (abstract).Google Scholar
  16. 16.
    Fisher R, DeVita VT, Johnson BL, Simon R, Young RC (1977). Prognostic factors for response and survival in adults with advanced non Hodgkin’s lymphoma. Am J Med 63:177–180.PubMedCrossRefGoogle Scholar
  17. 17.
    Cabanillas F, Burke JS, Smith TL, Moon ME, Butler JJ, Rodriguez V (1978). Factors predicting for response and survival in adults with advanced non Hodgkin’s lymphoma. Arch Intern Med 138:413–417.PubMedCrossRefGoogle Scholar
  18. 18.
    Swan F Jr, Velasquez WS, Tucker S, et al. (1989). A new serologic staging system for large cell lymphomas based on initial β2 microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518–1527.PubMedGoogle Scholar
  19. 19.
    Coiffier B, Gisselbrecht C, Vose JM, et al. (1991). Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etude des lymphomes Agressifs. J Clin Oncol 9:211–219.PubMedGoogle Scholar
  20. 20.
    Shipp MA, Harrington DP, Anderson JR, et al. (1993). A predictive model for aggressive NHL: the International Non Hodgkin’s Lymphoma Prognostic Factor Project. N Engl J Med 329:987–992.CrossRefGoogle Scholar
  21. 21.
    Fischer RI, DeVita VT, Hubbard SM, et al. (1983). Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 93:304–309.Google Scholar
  22. 22.
    Philip T, Hartmann O, Biron P, et al. (1988). High dose therapy and autologous bone marrow transplantation in partial remission after first line induction therapy for diffuse non Hodgkin’s lymphoma. J Clin Oncol 6:1118–1124.PubMedGoogle Scholar
  23. 23.
    Hagenbeek A, Verdonck L, Sonneveld P, Schouten H, van Imhoff G, van Putten W (1993). CHOP chemotherapy vs autologous BMT in slowly responding patients with intermediate and high grade malignant non Hodgkin’s lymphoma: results from a prospective randomized phase III trial in 294 patients. Blood 82:332a (abstract).Google Scholar
  24. 24.
    Surbone A, Longo D, De Vita C Jr, et al. (1988). Residual masses in aggressive non Hodgkin’s lymphoma after combination chemotherapy: signification and management. J Clin Oncol 6:1832–1837.PubMedGoogle Scholar
  25. 25.
    Cohen-Haguenauer O, Brice P, Gaci M, et al. (1993). Apport de la scintigraphie au gallium-67 dans les lymphomes malins. Presse Med 22:521–525.PubMedGoogle Scholar
  26. 26.
    Philip T, Armitage O, Spitzer G, et al. (1987). High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high grade non Hodgkin’s lymphoma. N Engl J Med 316:1493–1498.PubMedCrossRefGoogle Scholar
  27. 27.
    Phillips GL, Herzig RH, Lazarus HM, et al. (1983). Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 310:1557–1561.CrossRefGoogle Scholar
  28. 28.
    Takvorian T, Canellos GP, Ritz J, et al. (1987). Prolonged disease free survival after autologous bone marrow transplantation in patients with non Hodgkin’s lymphoma with a poor prognosis. N Engl J Med 316:1499–1505.PubMedCrossRefGoogle Scholar
  29. 29.
    Goldstone AH, MacMillan AK, Chopra R (1992). High dose therapy for the treatment of non Hodgkin’s lymphoma. In Armitage JO, Antmann KA (eds), High Dose Cancer Therapy: Pharmacology Haematopoietins, Stem Cells. Baltimore: Williams and Wilkins, pp. 662–670.Google Scholar
  30. 30.
    Bosly A, Coiffier B, Gisselbrecht C, et al. (1992). Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 10:1615–1623.PubMedGoogle Scholar
  31. 31.
    Philip T, Guglielmi A, Hagenbeek A, et al. (1992). The Parma international randomized prospective study in relapsed non Hodgkin’s lymphoma: second interim analysis of 172 patients. Blood 80:67a (abstract).Google Scholar
  32. 32.
    Appelbaum FR, Deisseroth AB, Graw RG, et al. (1987). Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 41:1059–1063.CrossRefGoogle Scholar
  33. 33.
    Philip T, Pinkerton R, Hartmann O, et al. (1986). The role of massive therapy with autologous bone marrow transplantation in Burkitt’s lymphoma. Clin Hematol 15:205–218.CrossRefGoogle Scholar
  34. 34.
    Blay J-Y, Philip T (1992). High dose therapy in Burkitt’s lymphoma. In Armitage JO, Antmann KA (eds), High Dose Cancer Therapy: Pharmacology Haematopoietins, Stem Cells. Baltimore: Williams and Wilkins, pp. 677–689.Google Scholar
  35. 35.
    Patte C, Michon J, Bouffet E, et al. (1992). High survival of childhood B-cell lymphoma and leukemia (ALL) as result of the LMB89 protocol of the SFOP. Proc Am Soc Clin Oncol 11:340 (abstract).Google Scholar
  36. 36.
    Patte C, Leverger G, Rubie H, et al. (1993). High cure rate in B-cell (Burkitt’s) leukemia in the LMB89 protocol of the SFOP. Proc Am Soc Clin Oncol 12:317 (abstract).Google Scholar
  37. 37.
    Philip T, Meckenstock R, Deconnick E, et al. (1992). Treatment of poor prognosis Burkitt’s lymphoma in adults with the Societe Francaise d’Oncologie Pediatrique LMB Protocol — a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). Eur J Cancer 28A: 1954–1959.PubMedCrossRefGoogle Scholar
  38. 38.
    Ostronoff M, Soussain C, Zambon E, et al. (1992). Burkitt’s lymphoma in adults: a retrospective study of 46 cases. Nouv Rev Fr Hematol 34:389–397.PubMedGoogle Scholar
  39. 39.
    Patte C, Philip T, Rodary C, et al. (1991). High survival rate in advanced stage B cell lymphoma and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123–132.PubMedGoogle Scholar
  40. 40.
    Philip T, Hartmann O, Pinkerton R, et al. (1993). Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: a report from the Societe Francaise d’Oncologie Pediatrique. Blood 81:2003–2006.PubMedGoogle Scholar
  41. 41.
    Coleman CN, Picozzi VJ, Cox RS, et al. (1987). Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:399–404.Google Scholar
  42. 42.
    Morel P, Lepage E, Brice P, et al. (1992). Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10:1078–1085.PubMedGoogle Scholar
  43. 43.
    Milpied N, Ifrah N, Kuentz M, et al. (1989). Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 73:82–87.PubMedCrossRefGoogle Scholar
  44. 44.
    Santini G, Congui AM, Coser P, et al. (1991). Autologous bone marrow transplantation for adult advanced stage adult non Hodgkin’s lymphoma in first complete remission: a study of the NHLGSG. Leukemia 5(Suppl 1):42–45.PubMedGoogle Scholar
  45. 45.
    Verdonck LF, Dekker AW, Gijsberg C, et al. (1992). Autologous bone marrow transplantation for adult poor risk lymphoblastic lymphoma in first remission. J Clin Oncol 10:644–648.PubMedGoogle Scholar
  46. 46.
    Chopra R, Goldstone AH, Pearce R, et al. (1992). Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690–1695.PubMedGoogle Scholar
  47. 47.
    Horning SJ, Rosenberg SA (1984). The natural history of initially untreated low grade lymphoma non Hodgkin’s lymphoma. N Engl J Med 311:1471–1475.PubMedCrossRefGoogle Scholar
  48. 48.
    Lister TA, Cullen MH, Beard MEJ, et al. (1978). Comparison of combined and single agent chemotherapy in non Hodgkin’s lymphoma of favorable histological type. Br Med J 1:533–537.PubMedCrossRefGoogle Scholar
  49. 49.
    Young RC, Longo DL, Glatstein E, et al. (1988). The treatment of indolent lymphoma: watchful waiting vs aggressive combined modality treatment. Semin Haematol 25:11–16.Google Scholar
  50. 50.
    Mac Laughlin P, Fuller LM, Velasquez WS, et al. (1987). Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 5:867–874.Google Scholar
  51. 51.
    Matis LA, Young RS, Longo DL (1986). Nodular lymphoma: current concepts. CRC Crit Rev Oncol Hematol 5:171–181.CrossRefGoogle Scholar
  52. 52.
    Smalley RV, Andersen JW, Hawkins MJ, et al. (1992). Interferon alfa combined with cyto-toxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 327:1336–1341.PubMedCrossRefGoogle Scholar
  53. 53.
    Andersen JW, Smalley RV (1993). Interferon alfa plus chemotherapy for non-Hodgkin’s lymphoma: five-year follow-up. N Engl J Med 329:1821–1822 (letter).PubMedCrossRefGoogle Scholar
  54. 54.
    Solal-Celigny P, Lepage E, Brousse N, et al. (1993). Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N Engl J Med 329:1608–1614.PubMedCrossRefGoogle Scholar
  55. 55.
    Gribben JG, Freedman AS, Neuberg D, et al. (1991). Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525–1533.PubMedCrossRefGoogle Scholar
  56. 56.
    Gribben JG, Freedman AS, Woo SD, et al. (1991). All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275–3280.PubMedGoogle Scholar
  57. 57.
    Berinstein N, Reis MD, Ngan BY, et al. (1992). Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early and advanced stage follicular lymphoma. Proc Am Soc Clin Oncol 12:369 (abstract).Google Scholar
  58. 58.
    Freedman AS, Ritz J, Neuberg D, et al. (1991). Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non Hodgkin’s lymphoma. Blood 77:2524–2529.PubMedGoogle Scholar
  59. 59.
    Brenner MK, Rill DR, Moen RC, et al. (1993). Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85–86.PubMedCrossRefGoogle Scholar
  60. 60.
    Bierman P, Vose J, Armitage JO, et al. (1992). High dose chemotherapy followed by autologous hematopoietic rescue for follicular low grade lymphoma. Proc Am Soc Clin Oncol 11:317 (abstract).Google Scholar
  61. 61.
    Freedman A, Nadler LM (1992). Bone marrow transplantation in low grade non Hodgkin’s lymphoma. Marrow Transplant Rev 2:33–38.Google Scholar
  62. 62.
    Fouillard L, Gorin NC, Laporte JP, et al. (1991). Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin’s lymphoma. Eur J Haematol 46:279–284.PubMedCrossRefGoogle Scholar
  63. 63.
    Schouten HC, Colombat P, Verdonck P, et al. (1994). Autologous bone marrow transplantation for low grade lymphoma: the European Bone Marrow Transplant Group experience. Ann Oncol 5(Suppl 2):S147–S150.Google Scholar
  64. 64.
    Weisdorf DJ, Anerson JW, Glick JH, et al. (1992). Survival after relapse of low grade non Hodgkin’s lymphoma: implication for bone marrow transplantation. J Clin Oncol 10:942–947.PubMedGoogle Scholar
  65. 65.
    Rohatiner AZS, Price CGA, Arnott S, et al. (1990). Ablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. In Dicke KA, Armitage JO, Discke-Evinger MJ (eds), Autologous Bone Marrow Transplantation: Proceedings of the Fifth International Symposium. Omaha: University of Nebraska Medical Center, pp. 465–470.Google Scholar
  66. 66.
    Rohatiner AZS, Freedman A, Nadler L, et al. (1994). Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 5(Suppl 2):S143–S146.Google Scholar
  67. 67.
    Colombat P, Binet C, Linassier C, et al. (1992). High dose chemotherapy with autologous marrow transplantation in follicular lymphomas. Leuk Lymphoma 7:3–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Bastion Y, Brice P, Sonet A, et al. (1994). Autologous peripheral blood stem cell transplantation (PBSCT) in 40 patients with advanced follicular lymphoma. Proc Am Soc Clin Oncol 13:1255 (abstract).Google Scholar
  69. 69.
    Lungren JH, Hansen RM, Chitambar CR, et al. (1991). Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA identical and alternative donors. J Clin Oncol 9:1848–1859.Google Scholar
  70. 70.
    Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991). Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653.PubMedGoogle Scholar
  71. 71.
    Appelbaum FR, Sullivan KM, Buckner CD, et al. (1987). Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J CLin Oncol 5:1340–1347.PubMedGoogle Scholar
  72. 72.
    Phillips GL, Herzig RH, Lazarus HM, et al. (1986). High dose chemotherapy, fractionated total body irradiation, and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 4:480–488.PubMedGoogle Scholar
  73. 73.
    Klingemann HG, Grigg A, Wilkie-Boyd K, et al. (1991). Treatment with recombinant interferon alpha ealry after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306–3311.PubMedGoogle Scholar
  74. 74.
    Gottlieb DJ, Prentice HG, Geslop HE, et al. (1989). Effects of recombinant IL-2 administration on cytotoxic function following high dose chemo-radiotherapy for hematological malignancy. Blood 74:2335–2342.PubMedGoogle Scholar
  75. 75.
    Kennedy MJ, Vogelsang GB, Jones RJ, et al. (1994). Phase I trial of interferon gamma to potentiate cyclosporine induced graft versus host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249–257.PubMedGoogle Scholar
  76. 76.
    Kessinger A, Armitage JO, Smith DM, et al. (1989). High dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 74:1260–1265.PubMedGoogle Scholar
  77. 77.
    Brice P, Marolleau JP, Dombret H, et al. (1992). Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. Bone Marrow Transplant 9:337–342.PubMedGoogle Scholar
  78. 78.
    Vose JM, Anderson JR, Kessinger A, et al. (1993). High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 11:1846–1851.PubMedGoogle Scholar
  79. 79.
    Liberti G, Pearce R, Taghipour G, Majolino I, Goldstone AH (1994). Comparison of peripheral blood stem cell and autologous bone marrow transplantation for lymphoma patients: a case control analysis of the EBMT registry data. Ann Oncol 5(S2):S151–S153.Google Scholar
  80. 80.
    Schwartzenberg LS, Birch R, Haselton B, et al. (1992). Peripheral blood stem cell mobilisation by chemotherapy with and without rG-CSF J Haematother 1:317–327.CrossRefGoogle Scholar
  81. 81.
    Sheridan WP, Begley CG, Juttner CA, et al. (1992). Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640–644.PubMedCrossRefGoogle Scholar
  82. 82.
    Nemunaitis J, Rabinowe SN, Singer JW, et al. (1991). Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773–1778.PubMedCrossRefGoogle Scholar
  83. 83.
    Gorin N-C, Coiffier B, Hayat M, et al. (1992). Recombinant human GM-CSF after high dose chemotherapy and autologous bone marrow transplantation with unpurged and pruged marrow in non Hodgkin’s lymphoma. Blood 80:1149–1157.PubMedGoogle Scholar
  84. 84.
    Gisselbrecht C, Prentice HG, Bacigalupo A, Biron P, Milpied N, Rubie H, Cunningham D, Legros M, Pico JL, Linch DC, Burnett AK, Scarffe JH, Siegert W, Yver A (1994). Placebo controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 343:696–700.PubMedCrossRefGoogle Scholar
  85. 85.
    Spitzer G, Adkins DR, Spencer V, et al. (1994). Randomized study of growth factors post-peripheral blood stem cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:661–670.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Jean-Yves Blay
  • Thierry O. Philip

There are no affiliations available

Personalised recommendations